Abstract Body (Do not enter title and authors here): Introduction: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) associated with improvement in glycemic and other metabolic conditions, and demonstrated cardiovascular (CV) safety. Several trials have demonstrated a reduction in major adverse cardiovascular events (MACE) with GLP-1 RAs, while demonstrating a reduction in heart failure risk in these same studies has been less conclusive. SURPASS-CVOT is the first cardiovascular outcome trial utilizing an active comparator, the cardioprotective agent dulaglutide, to evaluate the effects of tirzepatide in adults with T2D, established CV disease (CVD), and elevated risk for MACE.
Research Questions: To evaluate the effect of tirzepatide on MACE-3 and heart failure (HF) events in patients with a history of HF and relevant subgroups of the study population.
Methods: In this prespecified analysis, we examined the CV effects of tirzepatide (maximum tolerated dose of up to 15 mg) compared with dulaglutide 1.5 mg in patients with and without a history of HF at baseline. CV effects included the time to first occurrence of composite (CV deaths or HF events requiring hospitalization and/or urgent HF visit) and individual outcomes of HF, as well as MACE-3 (CV deaths, myocardial infarction, or stroke). The effect on HF events was also analysed in participants according to baseline BMI, HbA1c values, NYHA, chronic kidney disease, coronary artery disease, and diuretic use.
Results: Difference in listed outcomes and baseline characteristics between participants treated with tirzepatide or dulaglutide will be presented and discussed.
Conclusions: The present analysis of SURPASS-CVOT (registered with ClinicalTrials.gov, NCT0425543) will contribute to the evaluation of the effect of tirzepatide compared with dulaglutide on heart failure and other CV risk in participants with T2D and CVD.